HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $59 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Belite Bio (NASDAQ:BLTE) and maintained a price target of $59.
May 15, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Belite Bio and maintained a price target of $59.
The reiteration of a Buy rating and the maintenance of a $59 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100